News | Brachytherapy Systems | July 20, 2017

Electronic Brachytherapy Comparable to Mohs Surgery in Early-Stage Non-Melanoma Skin Cancer Treatment

Results of new study showed no statistically significant difference in recurrence of cancer at mean follow-up of 3.4 years

Electronic Brachytherapy Comparable to Mohs Surgery in Early-Stage Non-Melanoma Skin Cancer Treatment

July 20, 2017 — Rates of recurrence in early-stage non-melanoma skin cancer (NMSC) patients were virtually identical if they were treated with iCAD’s Xoft Axxent Electronic Brachytherapy (eBx) System or Mohs micrographic surgery, according to a new study. Mohs micrographic surgery is accepted as the most effective technique for removing basal cell carcinoma and squamous cell carcinoma, the two most common skin cancers. 

The results of the matched-pair cohort study of 369 patients were published online in the peer-reviewed Journal of Contemporary Brachytherapy.

“In recent years, we have seen substantial clinical evidence indicating that electronic brachytherapy offers comparable results to Mohs surgery in appropriately selected early-stage non-melanoma skin cancer patients,” said Rakesh Patel, M.D., lead investigator of the study, radiation oncologist and medical director, Department of Radiation Oncology, Good Samaritan Hospital, Los Gatos, Calif. “These data provide an entirely new level of clinical research confirming that treatment with eBx can help patients achieve similar low rates of recurrence with excellent cosmetic outcomes compared to Mohs surgery.”

The study compared clinical outcomes of patients treated with eBx and Mohs surgery at different treatment centers. In the population of 369 patients, a total of 188 were treated with eBx and 181 with Mohs surgery. Data reflected treatment of 416 lesions (208 in the eBx group and 208 in the Mohs surgery group), including 226 basal cell carcinomas and 190 squamous cell carcinomas. At a mean follow up of 3.4 years, 99.5 percent of eBx patients and 100 percent of Mohs surgery patients remained recurrence free. Statistics provided by the American College of Mohs Surgery state that Mohs surgery has a success rate “up to 99 percent.” Overall incidence of toxicity was similar in both treatment groups. In addition, physician-rated cosmetic outcomes were either “excellent” or “good” in 97.6 percent of eBx-treated lesions and 95.7 percent of Mohs surgery-treated lesions.

Results from patients treated with eBx in this study are consistent with the results from a growing body of additional clinical research assessing outcomes with eBx in the treatment of early-stage NMSC. An earlier outcomes study of 297 lesions with up to 63 months of follow-up (mean 16.5 months) showed only one recurrence and excellent cosmesis in 100 percent of patients at years 4-5. A separate study of 524 lesions treated with eBx with mean follow-up of 12.5 months showed a 0.7 percent recurrence rate.

“Our goal in treatment of NMSC is to eliminate the lesion while preserving function in the region affected by cancer,” Patel added. “These results indicate that eBx can achieve these goals without putting patients at higher risk of recurrence or complications.”

The Xoft System is U.S. Food and Drug Administration (FDA)-cleared, CE marked, and licensed in a growing number of countries for the treatment of cancer anywhere in the body, including early-stage breast cancer, gynecological cancers and non-melanoma skin cancer.

For more information: www.xoftinc.com

Related Content

ZON-PTC in Clinical Use With RayStation 8B and Hyperscan
News | Treatment Planning | March 19, 2019
Zuid-Oost Nederland Protonen Therapie Centrum (ZON-PTC), Maastricht, Netherlands, recently treated its first patient...
Older Biologic Age Linked to Elevated Breast Cancer Risk
News | Women's Health | March 19, 2019
Biologic age, a DNA-based estimate of a person’s age, is associated with future development of breast cancer, according...
HeartFlow Analysis Successfully Stratifies Heart Disease Patients at One Year
News | CT Angiography (CTA) | March 19, 2019
Late-breaking results confirm the HeartFlow FFRct (fractional flow reserve computed tomography) Analysis enables...
PET Scans Show Biomarkers Could Spare Some Breast Cancer Patients from Chemotherapy
News | PET Imaging | March 18, 2019
A new study positron emission tomography (PET) scans has identified a biomarker that may accurately predict which...
SyncVision iFR Co-registration from Philips Healthcare maps iFR pressure readings onto angiogram.

SyncVision iFR Co-registration from Philips Healthcare maps iFR pressure readings onto angiogram. Results from an international study presented at #ACC19 show that pressure readings in coronary arteries may identify locations of stenoses remaining after cardiac cath interventions.

Feature | Cardiac Imaging | March 18, 2019 | By Greg Freiherr
As many as one in four patients who undergo cath lab interventions can benefit from a technology that identifies the
Non-Contrast MRI Effective in Monitoring MS Patients
News | Neuro Imaging | March 18, 2019
Brain magnetic resonance imaging (MRI) without contrast agent is just as effective as the contrast-enhanced approach...
Bay Labs Announces New Data on EchoGPS, AutoEF AI Software at ACC.19
News | Cardiovascular Ultrasound | March 15, 2019
Artificial intelligence (AI) company Bay Labs announced the presentation of two studies assessing performance of the...
What to Expect from the Proton Therapy Market in 2019-2020
News | Proton Therapy | March 13, 2019
The number of new particle therapy rooms ordered worldwide dropped by almost 20 percent in 2018, according to a new...
CT, Mammograms Offer Clues to Preventing Heart Problems After Cancer Treatment
News | Cardio-oncology | March 13, 2019
An imaging procedure commonly performed before starting cancer treatment can provide valuable clues about a patient's...
Iron Measurements With MRI Reveal Stroke's Impact on Brain

Images show illustrative examples of visual R2? modifications within substantia nigra (SN) at baseline (24-72 h) and follow-up (1 y) in striatum (participants 1 and 2) and control groups (participants 3 and 4). Image courtesy of the Radiological Society of North America (RSNA).

News | Stroke | March 12, 2019
March 12, 2019 — A simple ...